866-997-4948(US-Canada Toll Free)

Neutropenia Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Oncology

No. of Pages : 104 Pages


Global Markets Directs, \'Neutropenia Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Neutropenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neutropenia. 

Neutropenia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Neutropenia.
  • A review of the Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Neutropenia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Neutropenia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Neutropenia Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Neutropenia 11
Neutropenia Therapeutics under Development by Companies 13
Neutropenia Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Neutropenia Therapeutics Products under Development by Companies 21
Neutropenia Therapeutics Products under Investigation by Universities/Institutes 23
Companies Involved in Neutropenia Therapeutics Development 24
Amgen Inc. 24
GlaxoSmithKline plc 25
Gamida Cell Ltd. 26
Biocon Limited 27
Taiho Pharmaceutical Co., Ltd. 28
Ligand Pharmaceuticals Incorporated 29
Lupin Limited 30
NexMed, Inc. 31
Cleveland BioLabs, Inc. 32
Telik, Inc. 33
Zenotech Laboratories Limited 34
ProMetic Life Sciences Inc. 35
Lipoxen PLC 36
Green Cross Corporation 37
Asterion Ltd 38
Phage Biotechnology Corporation 39
Bolder Biotechnology, Inc. 40
Welichem Biotech Inc. 41
USV Limited. 42
PharmaEssentia Corporation 43
ImmuneRegen BioSciences, Inc. 44
Pfenex Inc. 45
Mycenax Biotech Inc. 46
Neutropenia Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 54
pegfilgrastim biosimilar - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Homspera - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pegfilgrastim - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CBLB-612 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ezatiostat hydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
peginterferon alfa-2b - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
WBI-2100 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
filgrastim - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
GCPGC - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
GC-003 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
GranNEX - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
(piperacillin sodium + tazobactam sodium) - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
micafungin sodium - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
amphotericin B - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
filgrastim - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
PBI-4050 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
granulocyte-colony stimulating factor biosimilar - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
HM-10460A - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
meropenem - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
filgrastim - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
micafungin sodium - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
filgrastim - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
BBT-007 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
pegfilgrastim - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
pegylated filgrastim Biosimilar - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
GSK-584433 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
LG-7455 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
ACN-8337 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
PBI-4265 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
PBI-4283 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
PBI-4299 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
pegfilgrastim Biosimilar - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
filgrastim - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
AFT-Granulocyte Colony Stimulating Factor - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Neutropenia Therapeutics Drug Profile Updates 90
Neutropenia Therapeutics - Dormant Products 95
Neutropenia Product Development Milestones 97
Featured News & Press Releases 97
May 30, 2012: Aequus Presents Proof Of Concept Data Of GlycoPolymer Technology At International Symposium For Polymer Therapeutics 97
Dec 12, 2011: Ligand Announces Positive Preclinical Data On Small-Molecule GCSF Receptor Agonist At ASH Annual Meeting 97
Nov 03, 2011: Telik Announces Publication Of Report Of Complete Response Of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra 98
Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million In Qualifying Therapeutic Discovery Project Grants 99
Nov 02, 2010: Nektar Signs $50m Manufacturing And Supply Agreement With Amgen 99
Oct 14, 2010: Apricus Bio Announces IND Filing For Nupen 100
Sep 26, 2010: Hospira Receives Australian Approval For Nivestim 100
Jun 10, 2010: Hospira Receives Approval For Nivestim In Europe For Prevention Of Febrile Neutropenia Associated With Chemotherapy 101
Jul 14, 2009: Maxygen Announces Positive Results of MAXY-G34 Phase IIa Study in Breast Cancer Patients 101
Oct 02, 2008: Maxygen Announces Plans to Reduce Spending and Revise Corporate Strategy on MAXY-G34 102

Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 104
Disclaimer 104

List of Table


Number of Products Under Development for Neutropenia, H1 2013 11
Products under Development for Neutropenia Comparative Analysis, H1 2013 12
Number of Products under Development by Companies, H1 2013 14
Number of Products under Development by Companies, H1 2013 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2013 16
Comparative Analysis by Late Stage Development, H1 2013 17
Comparative Analysis by Mid Clinical Stage Development, H1 2013 18
Comparative Analysis by Early Clinical Stage Development, H1 2013 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 20
Products under Development by Companies, H1 2013 21
Products under Development by Companies, H1 2013 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2013 23
Amgen Inc., H1 2013 24
GlaxoSmithKline plc, H1 2013 25
Gamida Cell Ltd., H1 2013 26
Biocon Limited, H1 2013 27
Taiho Pharmaceutical Co., Ltd., H1 2013 28
Ligand Pharmaceuticals Incorporated, H1 2013 29
Lupin Limited, H1 2013 30
NexMed, Inc., H1 2013 31
Cleveland BioLabs, Inc., H1 2013 32
Telik, Inc., H1 2013 33
Zenotech Laboratories Limited, H1 2013 34
ProMetic Life Sciences Inc., H1 2013 35
Lipoxen PLC, H1 2013 36
Green Cross Corporation, H1 2013 37
Asterion Ltd, H1 2013 38
Phage Biotechnology Corporation, H1 2013 39
Bolder Biotechnology, Inc., H1 2013 40
Welichem Biotech Inc., H1 2013 41
USV Limited., H1 2013 42
PharmaEssentia Corporation, H1 2013 43
ImmuneRegen BioSciences, Inc., H1 2013 44
Pfenex Inc., H1 2013 45
Mycenax Biotech Inc., H1 2013 46
Assessment by Monotherapy Products, H1 2013 47
Assessment by Combination Products, H1 2013 48
Assessment by Stage and Route of Administration, H1 2013 50
Assessment by Stage and Molecule Type, H1 2013 53
Neutropenia Therapeutics Drug Profile Updates 90
Neutropenia Therapeutics Dormant Products 95
Neutropenia Therapeutics Dormant Products (Contd..1) 96

List of Chart


Number of Products under Development for Neutropenia, H1 2013 11
Products under Development for Neutropenia Comparative Analysis, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 16
Late Stage Products, H1 2013 17
Mid Clinical Stage Products, H1 2013 18
Early Clinical Stage Products, H1 2013 19
Discovery and Pre-Clinical Stage Products, H1 2013 20
Assessment by Monotherapy Products, H1 2013 47
Assessment by Combination Products, H1 2013 48
Assessment by Route of Administration, H1 2013 49
Assessment by Stage and Route of Administration, H1 2013 50
Assessment by Molecule Type, H1 2013 51
Assessment by Stage and Molecule Type, H1 2013 52

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *